New York, NY
Ketamine Therapy clinics in New York
New York has multiple clinics offering ketamine therapy, a fast growing segment for treatment resistant depression, PTSD, chronic pain, and anxiety. New York requires prescribers to hold a DEA registration and state controlled substance license; Spravato REMS programs are well established across the state. Most New York clinics deliver IV ketamine infusions in a monitored clinical setting, typically across a 6 session induction protocol, followed by maintenance infusions. Spravato (esketamine), the FDA approved nasal spray for treatment resistant depression, is available in New York only at REMS certified clinics and is often covered by insurance when medical necessity is documented. Compounded ketamine lozenges and troches are also prescribed in New York, sometimes through telehealth platforms like Mindbloom, Joyous, and Innerwell, subject to Ryan Haight Act and DEA special registration considerations. Local pricing in New York sits in the premium range: single IV infusions run 600 to 1,000 dollars, a full 6 session protocol lands at 3,600 to 6,000, and Spravato copays depend on insurance coverage. A reputable New York ketamine clinic will pair pharmacology with integration support, monitor vitals during infusion, and have a clear crisis and follow up plan.
Fountain Health NYC
- IV Therapy
- Ketamine Therapy
- Peptide Therapy
- Hormone Replacement Therapy (HRT)
Patients Medical PC, Functional and Holistic Medicine
- Ozone Therapy
- Multiple Sclerosis (MS) Treatment
- Ketamine Therapy
- Arthritis Treatment
- Chelation Therapy
LP Wellness & Aesthetics
- PRP Therapy
- Shockwave Therapy
- IV Therapy
- Ketamine Therapy
- Arthritis Treatment
Hudson Mind
- Transcranial Magnetic Stimulation (TMS)
- Ketamine Therapy
- Psychedelic Therapy
Regulatory context
A note on New York's ketamine therapy rules.
Ketamine is a DEA Schedule III controlled substance, FDA-approved as a dissociative anesthetic and used off-label for treatment-resistant depression, PTSD, and chronic pain. The FDA approved esketamine (Spravato) in 2019 for treatment-resistant depression under a Risk Evaluation and Mitigation Strategy (REMS) program that requires in-office administration at certified sites. MDMA-assisted therapy remains Schedule I; the FDA issued a Complete Response Letter in August 2024 to Lykos Therapeutics on its MDMA new drug application. Psilocybin is Schedule I and holds FDA Breakthrough Therapy designation through sponsors such as Compass Pathways and Usona, but has not received FDA approval. Oregon Measure 109 (passed 2020, operational 2023) created a state psilocybin service center framework, and Colorado Proposition 122 (2022) authorized regulated healing centers.
-
S 3520 / Psilocybin Assisted Therapy (2023)
Proposed a state psilocybin therapy framework; pending. -
A 114 / Psychedelic Decriminalization (2023)
Proposed decriminalization of possession and use of psilocybin, MDMA, DMT, mescaline, and ibogaine; pending. -
New York Public Health Law Article 33
Mirrors federal scheduling and governs controlled substance prescribing; requires NY-specific practitioner registration.
New York enforces federal and state scheduling. The New York State Bureau of Narcotic Enforcement (BNE) requires practitioners to obtain a New York State Controlled Substance License in addition to federal DEA. The Office of Professional Medical Conduct oversees prescriber discipline. DEA enforcement on ketamine clinics focuses on diversion and Ryan Haight Act telehealth compliance. New York PMP (I-STOP) requires electronic prescribing for controlled substances.